Frank Amato is CEO and President of SYNAPS Dx. Previously, after two decades in the pharmaceutical and biotech industries he was President, CEO, and Director of electroCore, a NASDAQ-traded bioelectronic medicine company focused on treating neurological conditions. Frank is an accomplished leader with a track record of consistently delivering
strong results. Prior to his tenure at electroCore, Frank was Vice President of the Specialty Commercial Operations Group at Merck, which comprised 9 specialty therapeutic divisions. He had responsibility for leading approximately 2,000 employees, generating $4.5b in annual revenue across 16 different pharmaceutical products. After Merck’s acquisition of Schering-Plough, he led the integration of approximately 3,000 employees into the new company. In addition to his day-to-day business responsibilities, Amato was accountable for various aspects of due diligence, negotiation, integration, and launching products in neuroscience, virology, and ophthalmology.
